Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update

CY6463 administration resulted in improvement in the levels of various neuroinflammatory biomarkers, including alpha-2-macroglobulin (A2M) and Complement C3 (C3).